MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Book Value 2011-2026 | BSX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.7 B | 39.4 B | 35.1 B | 32.5 B | 32.2 B | 30.8 B | 13.9 B | 8.73 B | 7.01 B | 6.73 B | 6.32 B | 6.46 B | 6.54 B | 6.87 B | 11.4 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.7 B | 6.32 B | 19.2 B |
Quarterly Book Value Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.7 B | 41.6 B | 40.1 B | 38.1 B | 37.1 B | 36.7 B | 34 B | 33.6 B | 32.9 B | 32.5 B | 31.9 B | - | 32.3 B | 32.2 B | 31.9 B | 31.2 B | 30.9 B | 30.8 B | 30.8 B | 30.8 B | 30.8 B | 30.6 B | 30.6 B | 30.6 B | 30.6 B | 21 B | 21 B | 21 B | 21 B | 19 B | 19 B | 19 B | 19 B | 18.1 B | 18.1 B | 18.1 B | 18.1 B | 18.1 B | 18.1 B | 18.1 B | 18.1 B | 17 B | 17 B | 17 B | 17 B | 16.6 B | 16.6 B | 16.6 B | 16.6 B | 17.2 B | 17.2 B | 17.2 B | 17.2 B | 21.3 B | 21.3 B | 21.3 B | 21.3 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 42.7 B | 16.6 B | 25 B |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
129 M | $ 32.67 | 5.42 % | $ 1.5 B |  USA |
 |
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.24 | 2.47 % | $ 1.65 B | USA |
 |
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M |  China |
 |
ClearPoint Neuro
CLPT
|
28 M | $ 9.36 | 3.2 % | $ 265 M | USA |
 |
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.82 B | $ 38.24 | 4.28 % | $ 5.7 K | USA |
 |
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | USA |
 |
FONAR Corporation
FONR
|
146 M | $ 18.61 | 0.13 % | $ 122 M | USA |
 |
Electromed
ELMD
|
43.2 M | $ 24.41 | 2.89 % | $ 206 M | USA |
 |
Globus Medical
GMED
|
4.57 B | $ 91.72 | 1.91 % | $ 12.4 B | USA |
 |
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.34 | -1.82 % | $ 125 M |  France |
 |
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | USA |
 |
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.89 | 3.28 % | $ 1.15 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 9.62 | 3.11 % | $ 741 M | USA |
 |
Align Technology
ALGN
|
3.85 B | $ 178.59 | 7.02 % | $ 13.4 B | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.75 B | $ 87.43 | 2.73 % | $ 3.04 B | USA |
 |
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.18 | 2.63 % | $ 380 M | USA |
 |
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
LivaNova PLC
LIVN
|
1.2 B | $ 64.67 | 1.78 % | $ 3.53 B |  Britain |
 |
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | USA |
 |
LENSAR
LNSR
|
-12.2 M | $ 5.67 | 0.71 % | $ 67.8 M | USA |
 |
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M |  Canada |
 |
Medtronic PLC
MDT
|
48.3 B | $ 88.04 | 1.87 % | $ 113 B | USA |
 |
Butterfly Network
BFLY
|
169 M | $ 4.18 | 3.21 % | $ 885 M | USA |
 |
Myomo
MYO
|
11.4 M | $ 0.68 | -0.3 % | $ 28.5 M | USA |
 |
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | USA |
 |
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | USA |
 |
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.64 | 4.94 % | $ 39.8 M | USA |
 |
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
111 M | $ 9.84 | 1.76 % | $ 352 M | USA |
 |
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | USA |
 |
Alphatec Holdings
ATEC
|
791 M | $ 11.45 | 3.76 % | $ 1.72 B | USA |
 |
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.14 | 10.68 % | $ 19.3 M | USA |
 |
CONMED Corporation
CNMD
|
1.03 B | $ 36.46 | 5.56 % | $ 1.13 B | USA |